Skip to main content
Some text as placeholder. In real life you can have the elements you have chosen. Like, text, images, lists, etc.
What are you looking for?

Retina Anti-VEGF Biosimilars: How to Prepare for the Coming Wave

Drugs that treat diseases of the retina, such as wet age-related macular degeneration (wet AMD), are treated with well-known brands. Physicians, patients and payers have relatively clear expectations for these products. But a coming wave of biosimilars in Europe, the U.S. and other markets could radically transform the treatment ecosystem.   

This example provides an opportunity to understand and prepare for the market transition for biosimilars ahead. By looking at the history of biosimilar introductions in other therapeutic areas, we can find valuable lessons valuable to biosimilar companies and brand owners alike. 

Download the White Paper Below.

To download the free whitepaper, fill out the form below:

Interested in Syneos Health?